Imaging of prostate cancer (PCa) has been transformed over the last 10 y through the development of novel prostate-specific membrane antigen (PSMA)–targeted PET radiotracers, which have shown enhanced sensitivity and specificity for PCa detection compared with conventional imaging techniques (bone scintigraphy, CT, and MRI) (1). The gene discussed is FOLH1; the disease is posterior cortical atrophy.